Topic Editors

Department of Experimental Pathology and Medicine, Mayo Clinic, Rochester, MN 55902, USA
Department of Pharmacology and Regenerative Medicine, Centre for Lung and Vascular Biology, College of Medicine, University of Illinois, Chicago, IL 60607, USA
Department of Biotechnology, Sahyadri Science College, Kuvempu University, Shimoga, India

Targeting Tumor Microvasculature of Malignant Metastatic Tumor

Abstract submission deadline
25 September 2024
Manuscript submission deadline
25 November 2024
Viewed by

Topic Information

Dear Colleagues,

The formation of the blood supply system is an important step in the cancerous transformation of cells, resulting in the penetration of tumor cells into the neighboring tissues and metastatic growth. Significant progress in the elucidation of mechanisms underlying tumor angiogenesis, along with the discovery of a great diversity of biomolecules involved in its regulation, have culminated in the development of a radically novel approach to antitumor therapy based on the search for effective inhibitors of tumor angiogenesis. Angiogenesis inhibitors target the neovascular development that is hypothesized as triggering tumor growth. The inhibitors that are involved in the search for the anti-angiogenesis process can be divided into five categories, based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block angiogenesis activators; 4) drugs that inhibit endothelial cell integrins or survival signaling; and 5) drugs with a currently unknown mechanism of action. In recent years, a great deal of research has been focused on the search for novel anti angiogenic drugs in the area of endogenous peptides, small organic molecules, microRNAs, cytotoxic molecules and so on. In this vein, we welcome original research, cutting-edge reviews and clinical trials. These should related, but not limited, to the aspects of the field listed: identification of small molecules, endogenous peptides, small organic molecules, microRNAs, cytotoxic molecules, antibody-drug conjugates, synergistic combination therapy, synthetic and natural biomolecules, nanoparticles and repurposing drugs, etc., against regulation of tumor angiogenesis and metastasis towards the identification of new anti-angiogenic drugs.

Dr. Prabhu Thirusangu
Dr. Vigneshwaran Vellingiri
Dr. Prabhakar Thippegowda
Topic Editors


  • anti-angiogenesis
  • tumor vasculature
  • metastasis
  • VEGF
  • angiogenesis inhibitors
  • anti-cancer

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
5.2 7.4 2009 17.9 Days CHF 2900 Submit
Current Oncology
2.6 2.6 1994 18 Days CHF 2200 Submit
Journal of Clinical Medicine
3.9 5.4 2012 17.9 Days CHF 2600 Submit
Journal of Personalized Medicine
3.4 2.6 2011 17.8 Days CHF 2600 Submit
- - 2021 18.3 Days CHF 1000 Submit is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with and has built a direct connection between MDPI journals and Authors are encouraged to enjoy the benefits by posting a preprint at prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers

This Topic is now open for submission.
Back to TopTop